在初级保健中数字检测痴呆症:一项随机临床试验
Malaz A Boustani1,2,3,4,5, Zina Ben Miled6, Arthur H Owora7,8
1Department of Medicine, Indiana University School of Medicine, Indianapolis.
JAMA network open
|November 10, 2025
概括
使用快速痴呆评级系统 (QDRS) 与被动数字标记器 (PDM) 结合,提前检测阿尔茨海默病和相关痴呆症 (ADRD) 得到了改善. 这种可扩展的方法提高了初级保健机构的ADRD诊断率.
科学领域:
- 老年学是指老年学的学科.
- 神经学 神经学
- 公共卫生 公共卫生
背景情况:
- 在初级保健中,检测阿尔茨海默病和相关痴呆症 (ADRD) 是一个挑战.
- 快速痴呆评级系统 (QDRS) 和被动数字标记 (PDM) 是用于早期ADRD检测的可扩展工具.
- 无论是QDRS还是PDM都可以集成到电子健康记录 (EHR) 中.
研究的目的:
- 评估QDRS和PDM对初级保健中每年新诊断ADRD的年率的综合影响.
- 评估综合ADRD查工具对诊断工作率的影响.
主要方法:
- 一个随机临床试验,涉及9个联邦合格的初级医疗保健诊所在印第安纳波利斯,印第安纳州.
- 诊所被随机分配到通常的护理,仅PDM,或QDRS加PDM.
- 包括65岁以上没有先前痴呆症诊断的成年人;分析了5325名患者.
主要成果:
- 与通常护理相比,QDRS加PDM方法显著增加了发生ADRD诊断的几率 (AOR,1.31).
- 在QDRS加PDM诊所中,ADRD诊断评估也更高 (AOR, 1.41).
- 单独PDM并没有显著增加ADRD诊断或评估率与通常护理相比.
结论:
- 联合QDRS加PDM方法对于初级保健中可扩展的早期ADRD检测是有效的.
- 这一综合战略通过提高诊断率,既有利于医疗保健系统,也有利于患者.
- 这些发现强调了数字工具和患者报告的措施在管理认知衰退方面的潜力.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
3.6K
相关概念视频
01:30Dementia
480
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
480
01:22Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K